Indoleamine 2,3-dioxygenase and tumor-induced tolerance

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1147-1154

  Munn, David H ^a   Mellor, Andrew L ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; PACLITAXEL; TRYPTOPHAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTHRITIS; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CELL CYCLE ARREST; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUNG CANCER; LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SENTINEL LYMPH NODE; SOLID TUMOR; T LYMPHOCYTE; TUMOR IMMUNOLOGY; UPREGULATION; UVEITIS;

ANIMALS; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS;

EID: 34248173331     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31178     Document Type: Review

References (125)

1. Boon, T., and van der Bruggen, P. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725-729.
2. Lennerz, V., et al. 2005. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. U. S. A. 102:16013-16018.
3. van der Bruggen, P., and van den Eynde, B.J. 2006. Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18:98-104.
4. Ercolini, A.M., et al. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201:1591-1602.
5. Ochsenbein, A.F., et al. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 96:2233-2238.
6. Spiotto, M.T., et al. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737-747.
7. Sotomayor, E.M., et al. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 98:1070-1077.
8. Yu, P., et al. 2005. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201:779-791.
9. Zhou, G., Drake, C.G., and Levitsky, H.I. 2006. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 107:628-636.
10. Maksimow, M., Miiluniemi, M., Marttila-Ichihara, F., Jalkanen, S., and Hanninen, A. 2006. Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood. 108:1298-1305.
11. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer. 5:263-274.
12. Stone, T.W., and Darlington, L.G. 2002. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1:609-620.
13. Schrocksnadel, K., Wirleitner, B., Winkler, C., and Fuchs, D. 2006. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta. 364:82-90.
14. Huang, A., et al. 2002. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br. J. Cancer. 86:1691-1696.
15. Iweala, O.I., and Nagler, C.R. 2006. Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunol. Rev. 213:82-100.
16. Munn, D.H., et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 281:1191-1193.
17. Mellor, A.L., et al. 2001. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2:64-68.
18. Muller, A.J., Duhadaway, J.B., Donover, P.S., Sutanto-Ward, E., and Prendergast, G.C. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11:312-319.
19. Grohmann, U., et al. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3:1097-1101.
20. Mellor, A.L., et al. 2003. Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171:1652-1655.
21. Chen, X., et al. 2006. Indoleamine 2,3-dioxygenase (IDO) is involved in promoting the development of anterior chamber-associated immune deviation. Immunol. Lett. 107:140-147.
22. Gurtner, G.J., Newberry, R.D., Schloemann, S.R., McDonald, K.G., and Stenson, W.F. 2003. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 125:1762-1773.
23. Kwidzinski, E., et al. 2005. Indolamine 2,3-dioxygenase is expressed in the CNS and downregulates autoimmune inflammation. FASEB J. 19:1347-1349.
24. Hayashi, T., et al. 2004. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114:270-279. doi:10.1172/JCI200421275.
25. Swanson, K.A., Zheng, Y., Heidler, K.M., Mizobuchi, T., and Wilkes, D.S. 2004. CDIIc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell Mol. Biol. 30:311-318.
26. Liu, H., Liu, L., Fletcher, B.S., and Visner, G.A. 2006. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J. 20:2384-2386.
27. Beutelspacher, S.C., et al. 2006. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by overexpression. Eur. J. Immunol. 36:690-700.
28. Uyttenhove, C., et al. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269-1274.
29. Munn, D.H., et al. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114:280-290. doi:10.1172/JCI200421583.
30. Grohmann, U., et al. 2001. IL-6 inhibits the tolerogenic function of CD8alpha(+) dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167:708-714.
31. Orabona, C., et al. 2006. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood. 107:2846-2854.
32. Munn, D.H., et al. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 297:1867-1870.
33. Munn, D.H., Sharma, M.D., and Mellor, A.L. 2004. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172:4100-4110.
34. Grohmann, U., et al. 2003. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J. Immunol. 171:2581-2587.
35. Braun, D., Longman, R.S., and Albert, M.L. 2005. A two step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic cell maturation. Blood. 106:2375-2381.
36. von Bergwelt-Baildon, M.S., et al. 2006. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 108:228-237.
37. Taylor, M.W., and Feng, G. 1991. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5:2516-2522.
38. Fallarino, F., et al. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9:1069-1077.
39. Frumento, G., et al. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196:459-468.
40. Terness, P., et al. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196:447-457.
41. Weber, W.P., et al. 2006. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur. J. Immunol. 36:296-304.
42. Chiesa, M.D., et al. 2006. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 108:4118-4125.
43. Belladonna, M.L., et al. 2006. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177:130-137.
44. Bauer, T.M., et al. 2005. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl. Int. 18:95-100.
45. Platten, M., et al. 2005. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 310:850-855.
46. Wang, J., et al. 2006. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281:22021-22028.
47. Bubnoff, D., et al. 2002. Fc-gamma RI induces the tryptophan degradation pathway involved in regulating T cell responses. J. Immunol. 169:1810-1816.
48. Munn, D.H., et al. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 22:633-642.
49. Fallarino, F., et al. 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176:6752- 6761.
50. Dong, J., Qiu, H., Garcia-Barrio, M., Anderson, J., and Hinnebusch, A.G. 2000. Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol. Cell. 6:269-279.
51. Harding, H.P., et al. 2003. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell. 11:619-633.
52. Wek, R.C., Jiang, H.Y., and Anthony, T.G. 2006. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 34:7-11.
53. Staveley-O'Carroll, K., et al. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 95:1178-1183.
54. Cuenca, A., et al. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63:9007-9015.
55. Gajewski, T.F., et al. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213:131-145.
56. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6:295-307.
57. Huang, A.Y., et al. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961-965.
58. Yu, P., Spiotto, M.T., Lee, Y., Schreiber, H., and Fu, Y.X. 2003. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med. 197:985-995.
59. van Mierlo, G., et al. 2004. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 173:6753-6759.
60. Nowak, A.K., et al. 2003. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170:4905-4913.
61. Hargadon, K.M., et al. 2006. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J. Immunol. 177:6081-6090.
62. Itano, A.A., and Jenkins, M.K. 2003. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 4:733-739.
63. Samy, E.T., Parker, L.A., Sharp, C.P., and Tung, K.S. 2005. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J. Exp. Med. 202:771-781.
64. Green, E.A., Choi, Y., and Flavell, R.A. 2002. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity. 16:183-191.
65. Wolvers, D.A., et al. 1999. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. J. Immunol. 162:1994-1998.
66. Kraal, G., Samsom, J.N., and Mebius, R.E. 2006. The importance of regional lymph nodes for mucosal tolerance. Immunol. Rev. 213:119-130.
67. Munn, D.H., and Mellor, A.L. 2006. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213:146-158.
68. Cochran, A.J., et al. 2006. Tumour-induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol. 6:659-670.
69. Lee, J.R., et al. 2003. Pattern of recruitment of immunoregulatory antigen presenting cells in malignant melanoma. Lab. Invest. 83:1457-1466.
70. Lee, J.H., et al. 2005. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11:107-112.
71. Baban, B., et al. 2005. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type 1 interferon-signaling following B7 ligation. Int. Immunol. 17:909-919.
72. Mellor, A.L., et al. 2005. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase- dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175:5601-5605.
73. Okamoto, A., et al. 2005. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11:6030-6039.
74. Ino, K., et al. 2006. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer. 95:1555-1561.
75. Brandacher, G., et al. 2006. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12:1144-1151.
76. Dunn, G.P., Koebel, C.M., and Schreiber, R.D. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848.
77. Nishikawa, H., et al. 2005. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. U. S. A. 102:9253-9257.
78. Sutmuller, R.P.M., et al. 2001. Synergism of cytoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoractive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
79. Yang, Y., Huang, C.T., Huang, X., and Pardoll, D.M. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5:508-515.
80. Fallarino, F., et al. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4:1206-1212.
81. Finger, E.B., and Bluestone, J.A. 2002. When ligand becomes receptor-tolerance via B7 signaling on DCs. Nat. Immunol. 3:1056-1057.
82. Hryniewicz, A., et al. 2006. CTLA-4 blockade decreases TGF-{beta}, indoleamine 2,3- dioxygenase, and viral RNA expression in tissues of SIV-mac251-infected macaques. Blood. 108:3834-3842.
83. Hiura, T., et al. 2005. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J. Immunol. 175:5058-5066.
84. Valzasina, B., Piconese, S., Guiducci, C., and Colombo, M.P. 2006. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 66:4488-4495.
85. Viguier, M., et al. 2004. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173:1444-1453.
86. Curti, A., et al. 2007. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 109:2871-2877.
87. Nowak, A.K., Robinson, B.W., and Lake, R.A. 2003. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63:4490-4496.
88. Broomfield, S., et al. 2005. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 65:7580-7584.
89. Dummer, W., et al. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110:185-192. doi:10.1172/JCI200215175.
90. King, C., Ilic, A., Koelsch, K., and Sarvetnick, N. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 117:265-277.
91. Wang, L.X., et al. 2005. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 65:10569-10577.
92. Brown, I.E., Blank, C., Kline, J., Kacha, A.K., and Gajewski, T.F. 2006. Homeostatic proliferation as an isolated variable reverses CD8+ T Cell anergy and promotes tumor rejection. J. Immunol. 177:4521-4529.
93. Awwad, M., and North, R.J. 1988. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 65:87-92.
94. Ghiringhelli, F., et al. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34:336-344.
95. Lutsiak, M.E., et al. 2005. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 105:2862-2868.
96. Beyer, M., et al. 2005. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 106:2018-2025.
97. Machiels, J.P., et al. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophagecolony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:3689-3697.
98. Weigel, B.J., Rodeberg, D.A., Krieg, A.M., and Blazar, B.R. 2003. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9:3105-3114.
99. Gattinoni, L., et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202:907-912.
100. Taieb, J., et al. 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176:2722-2729.
101. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
102. Morgan, R.A., et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126-129.
103. Hou, D.Y., et al. 2007. Inhibition of IDO in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with anti-tumor responses. Cancer Res. 67:792-801.
104. Podsypanina, K., Li, Y., and Varmus, H.E. 2004. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med. 2:24-34.
105. Peterson, A.C., et al. 1994. Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase. Med. Chem. Res. 3:531-544.
106. Rutella, S., et al. 2006. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood. 108:218-227.
107. Zhu, L., et al. 2006. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J. Immunol. 177:8226-8233.
108. Agaugue, S., Perrin-Cocon, L., Coutant, F., Andre, P., and Lotteau, V. 2006. 1-methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol. 177:2061-2071.
109. Hayashi, T., et al. 2001. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69:6156-6164.
110. Barcelo-Batllori, S., et al. 2002. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics. 2:551-560.
111. Odemuyiwa, S.O., et al. 2004. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J. Immunol. 173:5909-5913.
112. Beutelspacher, S.C., et al. 2006. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant. 6:1320-1330.
113. Yoshida, R., Urade, Y., Nakata, K., Watanabe, Y., and Hayashi, O. 1981. Specific induction of indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide in the mouse lung. Arch. Biochem. Biophys. 212:629-637.
114. Wingender, G., et al. 2006. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36:12-20.
115. Klinman, D.M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-258.
116. Speiser, D.E., et al. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739-746. doi:10.1172/JCI200523373.
117. Leichman, G., et al. 2005. CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study. J. Clin. Oncol. 23(Suppl.):7039.
118. Mellor, A., and Munn, D.H. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4:762-774.
119. Bendelac, A., and Medzhitov, R. 2002. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med. 195:F19-F23.
120. Moreau, M., et al. 2005. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J. Infect. Dis. 192:537-544.
121. Popov, A., et al. 2006. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest. 116:3160-3170. doi:10.1172/JCI28996.
122. Nam, K.O., Kang, W.J., Kwon, B.S., Kim, S.J., and Lee, H.W. 2005. The therapeutic potential of 4-1BB (CD137) in cancer. Curr. Cancer Drug Targets. 5:357-363.
123. Choi, B.K., Asai, T., Vinay, D.S., Kim, Y.H., and Kwon, B.S. 2006. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine. 34:233-242.
124. Seo, S.K., et al. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10:1088-1094.
125. Pure, E., Allison, J.P., and Schreiber, R.D. 2005. Breaking down the barriers to cancer immunotherapy. Nat. Immunol. 6:1207-1210.